Level Four Advisory Services LLC Sells 517 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Level Four Advisory Services LLC cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 13.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,313 shares of the biopharmaceutical company’s stock after selling 517 shares during the quarter. Level Four Advisory Services LLC’s holdings in Gilead Sciences were worth $268,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in GILD. Morgan Stanley lifted its stake in shares of Gilead Sciences by 0.9% in the 3rd quarter. Morgan Stanley now owns 16,909,619 shares of the biopharmaceutical company’s stock valued at $1,267,207,000 after acquiring an additional 158,794 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Gilead Sciences by 3.5% during the third quarter. Northern Trust Corp now owns 14,922,488 shares of the biopharmaceutical company’s stock valued at $1,118,291,000 after acquiring an additional 504,475 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Gilead Sciences by 3.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 9,783,195 shares of the biopharmaceutical company’s stock worth $792,547,000 after acquiring an additional 287,080 shares during the period. Charles Schwab Investment Management Inc. boosted its holdings in Gilead Sciences by 1.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 7,281,489 shares of the biopharmaceutical company’s stock valued at $589,873,000 after acquiring an additional 87,482 shares in the last quarter. Finally, Pacer Advisors Inc. increased its position in Gilead Sciences by 10.8% during the 4th quarter. Pacer Advisors Inc. now owns 5,046,652 shares of the biopharmaceutical company’s stock valued at $408,829,000 after purchasing an additional 493,920 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Morgan Stanley cut their target price on shares of Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. UBS Group cut their price target on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Maxim Group dropped their price target on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research note on Wednesday, May 1st. Mizuho reduced their price target on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating for the company in a research report on Thursday, February 22nd. Finally, Cantor Fitzgerald lowered their price objective on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 7th. Eleven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Hold” and a consensus price target of $83.69.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $67.80 on Thursday. The firm has a market capitalization of $84.47 billion, a P/E ratio of 188.33, a PEG ratio of 1.35 and a beta of 0.22. Gilead Sciences, Inc. has a fifty-two week low of $64.33 and a fifty-two week high of $87.86. The stock has a 50-day simple moving average of $68.77 and a two-hundred day simple moving average of $74.70. The company has a debt-to-equity ratio of 1.31, a quick ratio of 0.94 and a current ratio of 1.08.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating the consensus estimate of ($1.49) by $0.17. The company had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The firm’s revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the company posted $1.37 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post 3.74 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be issued a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 4.54%. The ex-dividend date of this dividend is Friday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is 855.56%.

Insider Buying and Selling at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total transaction of $146,360.00. Following the completion of the sale, the insider now owns 100,936 shares in the company, valued at approximately $7,386,496.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.